Tivic Health® Systems, Inc. (“Tivic”) (Nasdaq: TIVC), a commercial-phase health technology company that develops and commercializes bioelectronic medicine, announced today the launch of the second generation of Tivic ClearUP. The new and improved Tivic ClearUP 2.0, now with a new chip for power management for faster charge and longer battery life, is available starting today on TivicHealth.com.
ClearUP 2.0 is a clinically proven way to clear congestion and relieve sinus pain. It is an FDA-approved, 100% drug-free and non-addictive way to reduce sinus pain, pressure, sinus headaches, and congestion due to colds, flu, and allergies.
Based on clinical trials of ClearUP:
- 88% of subjects see meaningful improvement in congestion symptoms
- 74% experience pain relief on the first use
- 82% prefer ClearUP to other sinus treatments
- 10 minutes after treatment, patients reported relief of sinus pain
ClearUP provides an effective, non-invasive and drug-free alternative to over-the-counter medications, using gentle microcurrents to treat symptoms of sinus and nasal inflammation. The bioelectronic device locates treatment points along the cheek, nose and brow and emits gentle microcurrent stimulation for precise, targeted relief that you control. There is no mess, pills or sprays, and its ergonomic design fits in the palm of your hand so you can bring it everywhere you go and experience relief from sinus pain anytime, anywhere. The use of neuromodulation devices is growing throughout the medical industry, offering a new method of helping patients who do not respond to existing remedies.
About Tivic
Tivic Health Systems, Inc. is a commercial-phase health technology company delivering non-invasive bioelectronic treatments that provide consumers with a choice in the treatment of inflammation and certain other related conditions. For more information visit https://tivichealth.com @TivicHealth.
Forward-Looking Statements
This press release may contain “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Tivic Health Systems, Inc.’s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: unknown or unexpected defects with the new ClearUP 2.0 design; market and other conditions; supply chain constraints; macroeconomic factors; and unexpected costs, charges or expenses that reduce Tivic’s capital resources. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements. For a discussion of other risks and uncertainties, and other important factors, any of which could cause Tivic’s actual results to differ from those contained in the forward-looking statements, see Tivic’s filings with the SEC, including, its Annual Report on Form 10-K for the year ended December 31, 2022, filed with the SEC on March 31, 2023, under the heading “Risk Factors,” as well as the company’s subsequent filings with the SEC. Forward-looking statements contained in this press release are made as of this date, and Tivic Health Systems, Inc. undertakes no duty to update such information except as required by applicable law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240108148912/en/
Contacts
Max Borges Agency
Tivic@maxborgesagency.com
